Clinical trial
VG101 Phase I/II to Treat Vulvar and Vaginal Atrophy in Post-Menopausal Women
NCT00453089 · Bionovo, Industry · Unknown status
Key facts
| NCT number | NCT00453089 |
|---|---|
| Title | VG101 Phase I/II to Treat Vulvar and Vaginal Atrophy in Post-Menopausal Women |
| Official title | A Phase I/II Dose Escalation Clinical Trial to Assess Safety and Efficacy of VG101 to Treat the Symptoms of Vulvar and Vaginal Atrophy in Post-Menopausal Women |
| Lead sponsor | Bionovo, Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Vaginal Atrophy, Vulvar Atrophy |
| Intervention type | Drug |
| Interventions | VG101 |
| Enrollment | 40 |
| Start date | Jun 1, 2012 |
| Primary completion | Jun 1, 2013 |
| Completion | Aug 1, 2013 |
| First posted | Mar 28, 2007 |
| Last update posted | Feb 8, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: